Journal
EUROPEAN HEART JOURNAL
Volume 40, Issue 48, Pages 3937-+Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehz283
Keywords
Cardiovascular disease; Coronary artery disease; Inflammation; Novel therapies; Novel targets; Cytokines
Categories
Funding
- Netherlands Organization for Scientific Research (NWO) [016.130.676]
- EU [H2020-PHC-2015-667673]
- European Research Council (ERC) [CD40-INN 681492]
- ERC advanced grant [692511]
- German Centre for Cardiovascular Research (DZHK) high-risk high-volume (HRHV) grant
- European Research Council (ERC) [692511] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1 beta antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available